229 results on '"Bihl F."'
Search Results
2. Treatment-dependent Loss of Polyfunctional CD8+ T-cell Responses in HIV-infected Kidney Transplant Recipients Is Associated with Herpesvirus Reactivation
- Author
-
Gasser, O., Bihl, F., Sanghavi, S., Rinaldo, C., Rowe, D., Hess, C., Stablein, D., Roland, M., Stock, P., and Brander, C.
- Published
- 2009
- Full Text
- View/download PDF
3. Adaptive response in hepatitis B virus infection
- Author
-
Loggi, E., Gamal, N., Bihl, F., Bernardi, M., and Andreone, P.
- Published
- 2014
- Full Text
- View/download PDF
4. Strategies to manage hepatitis C virus (HCV) disease burden
- Author
-
Wedemeyer, H., Duberg, A. S., Buti, M., Rosenberg, W. M., Frankova, S., Esmat, G., Örmeci, N., Van Vlierberghe, H., Gschwantler, M., Akarca, U., Aleman, S., Balk, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., El-Sayed, M. H., Ergör, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Guimarães Pessôa, M., Hézode, C., Hindman, S. J., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marinho, R. T., Marotta, P., Mauss, S., Mendes Correa, M. C., Moreno, C., Müllhaupt, B., Myers, R. P., Nemecek, V., vrehus, A. L. H., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Sarrazin, C., Semela, D., Sherman, M., Shiha, G. E., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Vandijck, D., Vogel, W., Waked, I., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Negro, F., Sievert, W., and Gower, E.
- Published
- 2014
- Full Text
- View/download PDF
5. The present and future disease burden of hepatitis C virus (HCV) infection with todayʼs treatment paradigm
- Author
-
Razavi, H., Waked, I., Sarrazin, C., Myers, R. P., Idilman, R., Calinas, F., Vogel, W., Mendes Correa, M. C., Hézode, C., Lázaro, P., Akarca, U., Aleman, S., Balk, İ., Berg, T., Bihl, F., Bilodeau, M., Blasco, A. J., Brandão Mello, C. E., Bruggmann, P., Buti, M., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hindman, S. J., Hofer, H., Husa, P., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Marinho, R. T., Marotta, P., Mauss, S., Moreno, C., Murphy, K., Negro, F., Nemecek, V., Örmeci, N., vrehus, A. L. H., Parkes, J., Pasini, K., Peltekian, K. M., Ramji, A., Reis, N., Roberts, S. K., Rosenberg, W. M., Roudot-Thoraval, F., Ryder, S. D., Sarmento-Castro, R., Semela, D., Sherman, M., Shiha, G. E., Sievert, W., Sperl, J., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., Van Damme, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Cornberg, M., Müllhaupt, B., and Estes, C.
- Published
- 2014
- Full Text
- View/download PDF
6. Historical epidemiology of hepatitis C virus (HCV) in selected countries
- Author
-
Bruggmann, P., Berg, T., vrehus, A. L. H., Moreno, C., Brandão Mello, C. E., Roudot-Thoraval, F., Marinho, R. T., Sherman, M., Ryder, S. D., Sperl, J., Akarca, U., Balk, İ., Bihl, F., Bilodeau, M., Blasco, A. J., Buti, M., Calinas, F., Calleja, J. L., Cheinquer, H., Christensen, P. B., Clausen, M., Coelho, H. S. M., Cornberg, M., Cramp, M. E., Dore, G. J., Doss, W., Duberg, A. S., El-Sayed, M. H., Ergör, G., Esmat, G., Estes, C., Falconer, K., Félix, J., Ferraz, M. L. G., Ferreira, P. R., Frankova, S., García-Samaniego, J., Gerstoft, J., Giria, J. A., Gonçales, F. L., Jr, Gower, E., Gschwantler, M., Guimarães Pessôa, M., Hézode, C., Hofer, H., Husa, P., Idilman, R., Kåberg, M., Kaita, K. D. E., Kautz, A., Kaymakoglu, S., Krajden, M., Krarup, H., Laleman, W., Lavanchy, D., Lázaro, P., Marotta, P., Mauss, S., Mendes Correa, M. C., Müllhaupt, B., Myers, R. P., Negro, F., Nemecek, V., Örmeci, N., Parkes, J., Peltekian, K. M., Ramji, A., Razavi, H., Reis, N., Roberts, S. K., Rosenberg, W. M., Sarmento-Castro, R., Sarrazin, C., Semela, D., Shiha, G. E., Sievert, W., Stärkel, P., Stauber, R. E., Thompson, A. J., Urbanek, P., van Thiel, I., Van Vlierberghe, H., Vandijck, D., Vogel, W., Waked, I., Wedemeyer, H., Weis, N., Wiegand, J., Yosry, A., Zekry, A., Van Damme, P., Aleman, S., and Hindman, S. J.
- Published
- 2014
- Full Text
- View/download PDF
7. Corrigendum to 'Alcoholic and Nonalcoholic Liver Disease: Diagnostic Assessment and Therapeutic Perspectives'
- Author
-
Gitt S, Bihl F, Schepis F, Caputo F, and Berenguer M
- Abstract
[This corrects the article DOI: 10.1155/2019/8691502.].
- Published
- 2020
8. Erratum: Alcoholic and nonalcoholic liver disease: Diagnostic assessment and therapeutic perspectives (BioMed Research International (2019) 2019 (8691502) DOI: 10.1155/2019/8691502)
- Author
-
Gitt, S., Bihl, F., Schepis, F., Caputo, F., and Berenguer, M.
- Published
- 2020
9. Bakterielle Pneumonien
- Author
-
Bihl, F. and Cerny, A.
- Published
- 2002
- Full Text
- View/download PDF
10. LPS-hyporesponsiveness of mnd mice is associated with a mutation in Toll-like receptor 4
- Author
-
Bihl, F, Larivière, L, Qureshi, ST, Flaherty, L, and Malo, D
- Published
- 2001
- Full Text
- View/download PDF
11. Liver kidney microsomal type 1 antibodies reduce the CYP2D6 activity in patients with chronic hepatitis C virus infection
- Author
-
Girardin, F., Daali, Y., Gex-Fabry, M., Rebsamen, M., Roux-Lombard, P., Cerny, A., Bihl, F., Binek, J., Moradpour, D., Negro, F., and Desmeules, J.
- Published
- 2012
- Full Text
- View/download PDF
12. Two loci, Tmevp2 and Tmevp3, located on the telomeric region of chromosome 10, control the persistence of Theiler's virus in the central nervous system of mice
- Author
-
Bihl, F., Brahic, M., and Bureau, J.F.
- Subjects
Virus diseases -- Genetic aspects ,Mice as laboratory animals -- Research ,Central nervous system diseases -- Genetic aspects ,Genetic regulation -- Research ,Chromosomes -- Research ,Chromosome numbers -- Research ,Biological sciences - Abstract
Theiler's virus persistently infects the white matter of the spinal cord in susceptible strains of mice. This infection is associated with inflammation and primary demyelination and is studied as a model of multiple sclerosis. The H-2D gene is the major gene controlling viral persistence. However, the SJL/J strain is more susceptible than predicted by its [H-2.sup.s] haplotype. An (SJL/J x B10.S)[F.sub.1] x B10.S backcross was analyzed, and one quantitative trait locus (QTL) was located in the telomeric region of chromosome 10 close to the Ifng locus. Another one was tentatively mapped to the telomeric region of chromosome 18, close to the Mbp locus. We now report the study of 14 congenic lines that carry different segments of these two chromosomes. Although the presence of a QTL on chromosome 18 was not confirmed, two loci controlling viral persistence were identified on chromosome 10 and named Tmevp2 and Tmevp3. Furthermore, the Ifng gene was excluded from the regions containing Tmevp2 and Tmevp3. Analysis of the mode of inheritance of Tmevp2 and Tmevp3 identified an effect of sex, with males being more infected than females.
- Published
- 1999
13. A Rare Case of Classical Hodgkin Lymphoma Diagnosed 10 Years after Liver Transplant
- Author
-
Bihl F, Bühler M, Vannata B, Pereira Mestre R, Zhang L, and Stathis A
- Subjects
medicine.medical_specialty ,medicine.medical_treatment ,Hepatitis C virus ,Lymphoproliferative disorders ,Case Report ,030230 surgery ,Liver transplantation ,medicine.disease_cause ,lcsh:RC254-282 ,Gastroenterology ,03 medical and health sciences ,0302 clinical medicine ,hemic and lymphatic diseases ,Internal medicine ,medicine ,Epstein-Barr virus ,Transplantation ,business.industry ,Incidence (epidemiology) ,Immunosuppression ,lcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogens ,medicine.disease ,Epstein–Barr virus ,Posttransplant lymphoproliferative disorders ,surgical procedures, operative ,Oncology ,030220 oncology & carcinogenesis ,Complication ,business ,Hodgkin lymphoma - Abstract
Posttransplant lymphoproliferative disorders (PTLD) represent a rare and potentially life-threatening complication after liver transplantation. Classical Hodgkin lymphoma (cHL), with an incidence of approximately 1.8–3.4% of all PTLD cases, represents a minority of PTLD, mainly presenting as a late transplant complication. The main risk factors for the development of PTLD are Epstein-Barr virus (EBV) infection and intensive immunosuppression. However, other risk factors like hepatitis C virus may, together with EBV infection, contribute to the development of PTLD. Here we present a case of late-onset EBV-positive cHL that occurred 10 years after an unrelated donor liver transplantation. To our knowledge, this is the first report of cHL occurring with such a long interval after liver transplantation. Given the low incidence of cHL PTLD, there is little information regarding pathology, clinical characteristics, and management of this disease. The development of individual, risk-adapted treatments may improve the long-term outcome of cHL PTLD.
- Published
- 2017
- Full Text
- View/download PDF
14. Hepatobiliary and pancreatic: Acute liver failure caused by hepatocellular cancer
- Author
-
Bihl, F, Pedrinis, E, and Cerny, A
- Published
- 2004
15. Geoepidemiology of Primary Biliary Cholangitis: Lessons from Switzerland
- Author
-
Terziroli Beretta-Piccoli, B, Stirnimann, G, Cerny, A, Semela, D, Hessler, R, Helbling, B, Stickel, F, Kalid-de Bakker, C, Bihl, F, Giostra, E, Filipowicz Sinnreich, M, Oneta, C, Baserga, A, Invernizzi, P, Carbone, M, Mertens, J, Terziroli Beretta-Piccoli, B, Stirnimann, G, Cerny, A, Semela, D, Hessler, R, Helbling, B, Stickel, F, Kalid-de Bakker, C, Bihl, F, Giostra, E, Filipowicz Sinnreich, M, Oneta, C, Baserga, A, Invernizzi, P, Carbone, M, and Mertens, J
- Abstract
No data on primary biliary cholangitis (PBC) are available in Switzerland. We established a national patient cohort to obtain information on PBC phenotypes and disease course in Switzerland. Local databases in all university hospitals and in two large secondary centers were searched for case finding. In addition, all primary care physicians, gastroenterologists, rheumatologists, and dermatologists were invited to contribute patients from their own medical records. PBC diagnosis was centrally reviewed. Five hundred one PBC patients were identified, 474 were included in data analysis, and 449 of them were enrolled by tertiary centers. The catchment area accounts for approximately one third of the Swiss population or approximately 2.8 million inhabitants. The median age at diagnosis was 53 years, 84% were women, and 86% were anti-mitochondrial antibody positive. The median follow-up was 5.4 years, 12.6% experienced a liver-related endpoint. Splenomegaly was present at diagnosis in one quarter of patients and in half of male patients. Approximately one third were non-responders to ursodeoxycholic acid (UDCA). The median transplant-free survival at 10 years was 85%. The following variables were independently associated with poor outcome: low platelet count at baseline (HR = 0.99, p < 0.0001), elevated alkaline phosphatase at baseline (HR = 1.36, p < 0.0001), elevated bilirubin at baseline (HR = 1.11, p = 0.001), and elevated alanine aminotransaminase (HR = 1.35, p = 0.04) after 12 months of UDCA therapy. The AUROC for the UK-PBC risk score at 5, 10, and 15 years was 0.82. The AUROC for the Globe score at 5, 10, and 15 years was 0.77. Patients included in this study are currently being enrolled in a prospective nationwide registry with biobank, taking advantage of the collaboration network generated by this study. Our study provides the first snapshot of PBC in Switzerland, describing a diagnostic delay with one quarter of patients diagnosed when already in the cirrhotic
- Published
- 2018
16. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study
- Author
-
Blach, S. Zeuzem, S. Manns, M. Altraif, I. Duberg, A.-S. Muljono, D.H. Waked, I. Alavian, S.M. Lee, M.-H. Negro, F. Abaalkhail, F. Abdou, A. Abdulla, M. Abou Rached, A. Aho, I. Akarca, U. Al Ghazzawi, I. Al Kaabi, S. Al Lawati, F. Al Namaani, K. Al Serkal, Y. Al-Busafi, S.A. Al-Dabal, L. Aleman, S. Alghamdi, A.S. Aljumah, A.A. Al-Romaihi, H.E. Andersson, M.I. Arendt, V. Arkkila, P. Assiri, A.M. Baatarkhuu, O. Bane, A. Ben-Ari, Z. Bergin, C. Bessone, F. Bihl, F. Bizri, A.R. Blachier, M. Blasco, A.J. Brandao Mello, C.E. Bruggmann, P. Brunton, C.R. Calinas, F. Chan, H.L.Y. Chaudhry, A. Cheinquer, H. Chen, C.-J. Chien, R.-N. Choi, M.S. Christensen, P.B. Chuang, W.-L. Chulanov, V. Cisneros, L. Clausen, M.R. Cramp, M.E. Craxi, A. Croes, E.A. Dalgard, O. Daruich, J.R. De Ledinghen, V. Dore, G.J. El-Sayed, M.H. Ergor, G. Esmat, G. Estes, C. Falconer, K. Farag, E. Ferraz, M.L.G. Ferreira, P.R. Flisiak, R. Frankova, S. Gamkrelidze, I. Gane, E. Garcia-Samaniego, J. Khan, A.G. Gountas, I. Goldis, A. Gottfredsson, M. Grebely, J. Gschwantler, M. Guimaraes Pessoa, M. Gunter, J. Hajarizadeh, B. Hajelssedig, O. Hamid, S. Hamoudi, W. Hatzakis, A. Himatt, S.M. Hofer, H. Hrstic, I. Hui, Y.-T. Hunyady, B. Idilman, R. Jafri, W. Jahis, R. Janjua, N.Z. Jarčuška, P. Jeruma, A. Jonasson, J.G. Kamel, Y. Kao, J.-H. Kaymakoglu, S. Kershenobich, D. Khamis, J. Kim, Y.S. Kondili, L. Koutoubi, Z. Krajden, M. Krarup, H. Lai, M.-S. Laleman, W. Lao, W.-C. Lavanchy, D. Lazaro, P. Leleu, H. Lesi, O. Lesmana, L.A. Li, M. Liakina, V. Lim, Y.-S. Luksic, B. Mahomed, A. Maimets, M. Makara, M. Malu, A.O. Marinho, R.T. Marotta, P. Mauss, S. Memon, M.S. Mendes Correa, M.C. Mendez-Sanchez, N. Merat, S. Metwally, A.M. Mohamed, R. Moreno, C. Mourad, F.H. Mullhaupt, B. Murphy, K. Nde, H. Njouom, R. Nonkovic, D. Norris, S. Obekpa, S. Oguche, S. Olafsson, S. Oltman, M. Omede, O. Omuemu, C. Opare-Sem, O. Ovrehus, A.L.H. Owusu-Ofori, S. Oyunsuren, T.S. Papatheodoridis, G. Pasini, K. Peltekian, K.M. Phillips, R.O. Pimenov, N. Poustchi, H. Prabdial-Sing, N. Qureshi, H. Ramji, A. Razavi-Shearer, D. Razavi-Shearer, K. Redae, B. Reesink, H.W. Ridruejo, E. Robbins, S. Roberts, L.R. Roberts, S.K. Rosenberg, W.M. Roudot-Thoraval, F. Ryder, S.D. Safadi, R. Sagalova, O. Salupere, R. Sanai, F.M. Sanchez Avila, J.F. Saraswat, V. Sarmento-Castro, R. Sarrazin, C. Schmelzer, J.D. Schreter, I. Seguin-Devaux, C. Shah, S.R. Sharara, A.I. Sharma, M. Shevaldin, A. Shiha, G.E. Sievert, W. Sonderup, M. Souliotis, K. Speiciene, D. Sperl, J. Starkel, P. Stauber, R.E. Stedman, C. Struck, D. Su, T.-H. Sypsa, V. Tan, S.-S. Tanaka, J. Thompson, A.J. Tolmane, I. Tomasiewicz, K. Valantinas, J. Van Damme, P. Van Der Meer, A.J. Van Thiel, I. Van Vlierberghe, H. Vince, A. Vogel, W. Wedemeyer, H. Weis, N. Wong, V.W.S. Yaghi, C. Yosry, A. Yuen, M.-F. Yunihastuti, E. Yusuf, A. Zuckerman, E. Razavi, H. The Polaris Observatory HCV Collaborators
- Abstract
Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8–1·1) in 2015, corresponding to 71·1 million (62·5–79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation. © 2017 Elsevier Ltd
- Published
- 2017
17. Autoimmune liver disease serology in acute hepatitis E virus infection
- Author
-
Beretta-Piccoli, B. Terziroli, primary, Ripellino, P., additional, Gobbi, C., additional, Cerny, A., additional, Baserga, A., additional, Di Bartolomeo, C., additional, Bihl, F., additional, Deleonardi, G., additional, Melidona, L., additional, Grondona, A.G., additional, Mieli-Vergani, G., additional, Vergani, D., additional, and Muratori, L., additional
- Published
- 2018
- Full Text
- View/download PDF
18. LB1578 Identification and characterization of highly optimized RORγ inverse agonists for the topical treatment of psoriasis
- Author
-
Hervouet, C., primary, Bihl, F., additional, Ouvry, G., additional, Musicki, B., additional, Harris, C., additional, Bouix-peter, C., additional, Pascau, J., additional, Chaussade, C., additional, Piwnica, D., additional, Deret, S., additional, Julia, V., additional, Hennequin, L., additional, Vial, E., additional, and Hacini-Rachinel, F., additional
- Published
- 2018
- Full Text
- View/download PDF
19. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study.
- Author
-
Farag E., De Ledinghen V., Dore G.J., Papatheodoridis G., Pasini K., Peltekian K.M., Phillips R.O., Pimenov N., Poustchi H., Prabdial-Sing N., Qureshi H., Ramji A., Razavi-Shearer D., Razavi-Shearer K., Redae B., Reesink H.W., Ridruejo E., Robbins S., Roberts L.R., Roberts S.K., Rosenberg W.M., Roudot-Thoraval F., Ryder S.D., Safadi R., Sagalova O., Salupere R., Sanai F.M., Sanchez Avila J.F., Saraswat V., Sarmento-Castro R., Sarrazin C., Schmelzer J.D., Schreter I., Seguin-Devaux C., Shah S.R., Sharara A.I., Sharma M., Shevaldin A., Shiha G.E., Sonderup M., Souliotis K., Speiciene D., Sperl J., Starkel P., Stauber R.E., Stedman C., Struck D., Su T.-H., Sypsa V., Tan S.-S., Tanaka J., Thompson A.J., Tolmane I., Tomasiewicz K., Valantinas J., Van Damme P., Van Der Meer A.J., Van Thiel I., Van Vlierberghe H., Vince A., Vogel W., Wedemeyer H., Weis N., Wong V.W.S., Yaghi C., Yosry A., Yuen M.-F., Yunihastuti E., Yusuf A., Zuckerman E., Razavi H., Sievert W., Blach S., Zeuzem S., Manns M., Altraif I., Duberg A.-S., Muljono D.H., Waked I., Alavian S.M., Lee M.-H., Negro F., Abaalkhail F., Abdou A., Abdulla M., Abou Rached A., Aho I., Akarca U., Al Ghazzawi I., Al Kaabi S., Al Lawati F., Al Namaani K., Al Serkal Y., Al-Busafi S.A., Al-Dabal L., Aleman S., Alghamdi A.S., Aljumah A.A., Al-Romaihi H.E., Andersson M.I., Arendt V., Arkkila P., Assiri A.M., Baatarkhuu O., Bane A., Ben-Ari Z., Bergin C., Bessone F., Bihl F., Bizri A.R., Blachier M., Blasco A.J., Brandao Mello C.E., Bruggmann P., Brunton C.R., Calinas F., Chan H.L.Y., Chaudhry A., Cheinquer H., Chen C.-J., Chien R.-N., Choi M.S., Christensen P.B., Chuang W.-L., Chulanov V., Cisneros L., Clausen M.R., Cramp M.E., Craxi A., Croes E.A., Dalgard O., Daruich J.R., El-Sayed M.H., Ergor G., Esmat G., Estes C., Falconer K., Ferraz M.L.G., Ferreira P.R., Flisiak R., Frankova S., Gamkrelidze I., Gane E., Garcia-Samaniego J., Khan A.G., Gountas I., Goldis A., Gottfredsson M., Grebely J., Gschwantler M., Guimaraes Pessoa M., Gunter J., Hajarizadeh B., Hajelssedig O., Hamid S., Hamoudi W., Hatzakis A., Himatt S.M., Hofer H., Hrstic I., Hui Y.-T., Hunyady B., Idilman R., Jafri W., Jahis R., Janjua N.Z., Jarcuska P., Jeruma A., Jonasson J.G., Kamel Y., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis J., Kim Y.S., Kondili L., Koutoubi Z., Krajden M., Krarup H., Lai M.-S., Laleman W., Lao W.-C., Lavanchy D., Lazaro P., Leleu H., Lesi O., Lesmana L.A., Li M., Liakina V., Lim Y.-S., Luksic B., Mahomed A., Maimets M., Makara M., Malu A.O., Marinho R.T., Marotta P., Mauss S., Memon M.S., Mendes Correa M.C., Mendez-Sanchez N., Merat S., Metwally A.M., Mohamed R., Moreno C., Mourad F.H., Mullhaupt B., Murphy K., Nde H., Njouom R., Nonkovic D., Norris S., Obekpa S., Oguche S., Olafsson S., Oltman M., Omede O., Omuemu C., Opare-Sem O., Ovrehus A.L.H., Owusu-Ofori S., Oyunsuren T.S., Farag E., De Ledinghen V., Dore G.J., Papatheodoridis G., Pasini K., Peltekian K.M., Phillips R.O., Pimenov N., Poustchi H., Prabdial-Sing N., Qureshi H., Ramji A., Razavi-Shearer D., Razavi-Shearer K., Redae B., Reesink H.W., Ridruejo E., Robbins S., Roberts L.R., Roberts S.K., Rosenberg W.M., Roudot-Thoraval F., Ryder S.D., Safadi R., Sagalova O., Salupere R., Sanai F.M., Sanchez Avila J.F., Saraswat V., Sarmento-Castro R., Sarrazin C., Schmelzer J.D., Schreter I., Seguin-Devaux C., Shah S.R., Sharara A.I., Sharma M., Shevaldin A., Shiha G.E., Sonderup M., Souliotis K., Speiciene D., Sperl J., Starkel P., Stauber R.E., Stedman C., Struck D., Su T.-H., Sypsa V., Tan S.-S., Tanaka J., Thompson A.J., Tolmane I., Tomasiewicz K., Valantinas J., Van Damme P., Van Der Meer A.J., Van Thiel I., Van Vlierberghe H., Vince A., Vogel W., Wedemeyer H., Weis N., Wong V.W.S., Yaghi C., Yosry A., Yuen M.-F., Yunihastuti E., Yusuf A., Zuckerman E., Razavi H., Sievert W., Blach S., Zeuzem S., Manns M., Altraif I., Duberg A.-S., Muljono D.H., Waked I., Alavian S.M., Lee M.-H., Negro F., Abaalkhail F., Abdou A., Abdulla M., Abou Rached A., Aho I., Akarca U., Al Ghazzawi I., Al Kaabi S., Al Lawati F., Al Namaani K., Al Serkal Y., Al-Busafi S.A., Al-Dabal L., Aleman S., Alghamdi A.S., Aljumah A.A., Al-Romaihi H.E., Andersson M.I., Arendt V., Arkkila P., Assiri A.M., Baatarkhuu O., Bane A., Ben-Ari Z., Bergin C., Bessone F., Bihl F., Bizri A.R., Blachier M., Blasco A.J., Brandao Mello C.E., Bruggmann P., Brunton C.R., Calinas F., Chan H.L.Y., Chaudhry A., Cheinquer H., Chen C.-J., Chien R.-N., Choi M.S., Christensen P.B., Chuang W.-L., Chulanov V., Cisneros L., Clausen M.R., Cramp M.E., Craxi A., Croes E.A., Dalgard O., Daruich J.R., El-Sayed M.H., Ergor G., Esmat G., Estes C., Falconer K., Ferraz M.L.G., Ferreira P.R., Flisiak R., Frankova S., Gamkrelidze I., Gane E., Garcia-Samaniego J., Khan A.G., Gountas I., Goldis A., Gottfredsson M., Grebely J., Gschwantler M., Guimaraes Pessoa M., Gunter J., Hajarizadeh B., Hajelssedig O., Hamid S., Hamoudi W., Hatzakis A., Himatt S.M., Hofer H., Hrstic I., Hui Y.-T., Hunyady B., Idilman R., Jafri W., Jahis R., Janjua N.Z., Jarcuska P., Jeruma A., Jonasson J.G., Kamel Y., Kao J.-H., Kaymakoglu S., Kershenobich D., Khamis J., Kim Y.S., Kondili L., Koutoubi Z., Krajden M., Krarup H., Lai M.-S., Laleman W., Lao W.-C., Lavanchy D., Lazaro P., Leleu H., Lesi O., Lesmana L.A., Li M., Liakina V., Lim Y.-S., Luksic B., Mahomed A., Maimets M., Makara M., Malu A.O., Marinho R.T., Marotta P., Mauss S., Memon M.S., Mendes Correa M.C., Mendez-Sanchez N., Merat S., Metwally A.M., Mohamed R., Moreno C., Mourad F.H., Mullhaupt B., Murphy K., Nde H., Njouom R., Nonkovic D., Norris S., Obekpa S., Oguche S., Olafsson S., Oltman M., Omede O., Omuemu C., Opare-Sem O., Ovrehus A.L.H., Owusu-Ofori S., and Oyunsuren T.S.
- Abstract
Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of-and expansion on-the 2014 analysis, which reported 80 million (95% CI 64-103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1.0% (95% uncertainty interval 0.8-1.1) in 2015, corresponding to 71.1 million (62.5-79.4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation.Copyright © 2017 Elsevier Ltd
- Published
- 2017
20. Global prevalence and genotype distribution of hepatitis C virus infection in 2015: A modelling study
- Author
-
Blach, S, Zeuzem, S, Manns, M, Altraif, I, Duberg, AS, Muljono, DH, Waked, I, Alavian, SM, Lee, MH, Negro, F, Abaalkhail, F, Abdou, A, Abdulla, M, Abou Rached, A, Aho, I, Akarca, U, Al Ghazzawi, I, Al Kaabi, S, Al Lawati, F, Al Namaani, K, Al Serkal, Y, Al-Busafi, SA, Al-Dabal, L, Aleman, S, Alghamdi, AS, Aljumah, AA, Al-Romaihi, HE, Andersson, MI, Arendt, V, Arkkila, P, Assiri, AM, Baatarkhuu, O, Bane, A, Ben-Ari, Z, Bergin, C, Bessone, F, Bihl, F, Bizri, AR, Blachier, M, Blasco, AJ, Brandao Mello, CE, Bruggmann, P, Brunton, CR, Calinas, F, Chan, HLY, Chaudhry, A, Cheinquer, H, Chen, CJ, Chien, RN, Choi, MS, Christensen, PB, Chuang, WL, Chulanov, V, Cisneros, L, Clausen, MR, Cramp, ME, Craxi, A, Croes, EA, Dalgard, O, Daruich, JR, De Ledinghen, V, Dore, GJ, El-Sayed, MH, Ergor, G, Esmat, G, Estes, C, Falconer, K, Farag, E, Ferraz, MLG, Ferreira, PR, Flisiak, R, Frankova, S, Gamkrelidze, I, Gane, E, Garcia-Samaniego, J, Khan, AG, Gountas, I, Goldis, A, Gottfredsson, M, Grebely, J, Gschwantler, M, Guimaraes Pessoa, M, Gunter, J, Hajarizadeh, B, Hajelssedig, O, Hamid, S, Hamoudi, W, Hatzakis, A, Himatt, SM, Hofer, H, Hrstic, I, Hui, YT, Hunyady, B, Idilman, R, Jafri, W, Jahis, R, Janjua, NZ, Jarčuška, P, Jeruma, A, Jonasson, JG, Blach, S, Zeuzem, S, Manns, M, Altraif, I, Duberg, AS, Muljono, DH, Waked, I, Alavian, SM, Lee, MH, Negro, F, Abaalkhail, F, Abdou, A, Abdulla, M, Abou Rached, A, Aho, I, Akarca, U, Al Ghazzawi, I, Al Kaabi, S, Al Lawati, F, Al Namaani, K, Al Serkal, Y, Al-Busafi, SA, Al-Dabal, L, Aleman, S, Alghamdi, AS, Aljumah, AA, Al-Romaihi, HE, Andersson, MI, Arendt, V, Arkkila, P, Assiri, AM, Baatarkhuu, O, Bane, A, Ben-Ari, Z, Bergin, C, Bessone, F, Bihl, F, Bizri, AR, Blachier, M, Blasco, AJ, Brandao Mello, CE, Bruggmann, P, Brunton, CR, Calinas, F, Chan, HLY, Chaudhry, A, Cheinquer, H, Chen, CJ, Chien, RN, Choi, MS, Christensen, PB, Chuang, WL, Chulanov, V, Cisneros, L, Clausen, MR, Cramp, ME, Craxi, A, Croes, EA, Dalgard, O, Daruich, JR, De Ledinghen, V, Dore, GJ, El-Sayed, MH, Ergor, G, Esmat, G, Estes, C, Falconer, K, Farag, E, Ferraz, MLG, Ferreira, PR, Flisiak, R, Frankova, S, Gamkrelidze, I, Gane, E, Garcia-Samaniego, J, Khan, AG, Gountas, I, Goldis, A, Gottfredsson, M, Grebely, J, Gschwantler, M, Guimaraes Pessoa, M, Gunter, J, Hajarizadeh, B, Hajelssedig, O, Hamid, S, Hamoudi, W, Hatzakis, A, Himatt, SM, Hofer, H, Hrstic, I, Hui, YT, Hunyady, B, Idilman, R, Jafri, W, Jahis, R, Janjua, NZ, Jarčuška, P, Jeruma, A, and Jonasson, JG
- Abstract
Background The 69th World Health Assembly approved the Global Health Sector Strategy to eliminate hepatitis C virus (HCV) infection by 2030, which can become a reality with the recent launch of direct acting antiviral therapies. Reliable disease burden estimates are required for national strategies. This analysis estimates the global prevalence of viraemic HCV at the end of 2015, an update of—and expansion on—the 2014 analysis, which reported 80 million (95% CI 64–103) viraemic infections in 2013. Methods We developed country-level disease burden models following a systematic review of HCV prevalence (number of studies, n=6754) and genotype (n=11 342) studies published after 2013. A Delphi process was used to gain country expert consensus and validate inputs. Published estimates alone were used for countries where expert panel meetings could not be scheduled. Global prevalence was estimated using regional averages for countries without data. Findings Models were built for 100 countries, 59 of which were approved by country experts, with the remaining 41 estimated using published data alone. The remaining countries had insufficient data to create a model. The global prevalence of viraemic HCV is estimated to be 1·0% (95% uncertainty interval 0·8–1·1) in 2015, corresponding to 71·1 million (62·5–79·4) viraemic infections. Genotypes 1 and 3 were the most common cause of infections (44% and 25%, respectively). Interpretation The global estimate of viraemic infections is lower than previous estimates, largely due to more recent (lower) prevalence estimates in Africa. Additionally, increased mortality due to liver-related causes and an ageing population may have contributed to a reduction in infections. Funding John C Martin Foundation.
- Published
- 2017
21. A Rare Case of Classical Hodgkin Lymphoma Diagnosed 10 Years after Liver Transplant
- Author
-
Zhang, L., primary, Pereira Mestre, R., additional, Bihl, F., additional, Bühler, M., additional, Vannata, B., additional, and Stathis, A., additional
- Published
- 2017
- Full Text
- View/download PDF
22. 348 Topical RORγ inverse agonist alleviate preclinical models of psoriasis
- Author
-
Hervouet, C., primary, Bihl, F., additional, Ouvry, G., additional, Bouix-Peter, C., additional, Chaussade, C., additional, Piwnica, D., additional, Julia, V., additional, Hennequin, L., additional, Vial, E., additional, and Hacini-Rachinel, F., additional
- Published
- 2017
- Full Text
- View/download PDF
23. The health burden of primary biliary cholangitis in Switzerland: a cross-sectional study
- Author
-
Beretta-Piccoli, B.C.T., primary, Stirnimann, G., additional, Cerny, A., additional, Khalid-de Bakker, C., additional, Semela, D., additional, Hessler, R., additional, Giostra, E., additional, Helbling, B., additional, Stickel, F., additional, Bihl, F., additional, Invernizzi, P., additional, Mertens, J., additional, and Carbone, M., additional
- Published
- 2017
- Full Text
- View/download PDF
24. HEV as a cause of acute hepatitis acquired in Switzerland
- Author
-
Christinet, M.F., primary, Doerig, C., additional, Moulin, H., additional, Bihl, F., additional, Brunner, F., additional, Müllhaupt, B., additional, Semela, D., additional, Stickel, F., additional, Beretta-Piccoli, B.T., additional, Aubert, V., additional, Telenti, A., additional, Greub, G., additional, Sahli, R., additional, and Moradpour, D., additional
- Published
- 2017
- Full Text
- View/download PDF
25. The Th1/Th2 Balance Does Not Account for the Difference of Susceptibility of Mouse Strains to Theiler’s Virus Persistent Infection
- Author
-
Monteyne, P, Bihl, F., Levillayer, F, Brahic, M., Bureau, J, Virus Lents, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Mice, Inbred A ,T-Lymphocytes ,[SDV]Life Sciences [q-bio] ,Molecular Sequence Data ,Immunology ,chemical and pharmacologic phenomena ,Lymphocyte Activation ,Interferon-gamma ,Mice ,Mice, Congenic ,Th2 Cells ,Theilovirus ,Cardiovirus Infections ,Animals ,Immunology and Allergy ,Mice, Inbred BALB C ,Mice, Inbred C3H ,Base Sequence ,hemic and immune systems ,Th1 Cells ,Immunity, Innate ,Mice, Inbred C57BL ,Genes ,Mice, Inbred DBA ,Mice, Inbred CBA ,Cytokines ,Interleukin-2 ,Disease Susceptibility - Abstract
Theiler’s virus causes a persistent infection with demyelination that is studied as a model for multiple sclerosis. Inbred strains of mice differ in their susceptibility to viral persistence due to both H-2 and non-H-2 genes. A locus with a major effect on persistence has been mapped on chromosome 10, close to the Ifng locus, using a cross between susceptible SJL/J and resistant B10.S mice. We now confirm the existence of this locus using two lines of congenic mice bearing the B10.S Ifng locus on an SJL/J background, and we describe a deletion in the promoter of the Ifng gene of the SJL/J mouse. We studied the expression of IFN-γ, IL-2, IL-10, and IL-12 in the brains of SJL/J mice, B10.S mice, and the two lines of congenic mice during the first 2 wk following inoculation. We found a greater expression of IFN-γ and IL-2 mRNA in the brains of B10.S mice compared with those of SJL/J mice. Also, the ratio of IL-12 to IL-10 mRNA levels was higher in B10.S mice. However, the cytokine profiles were the same for the two lines of resistant congenic mice and for susceptible SJL/J mice. Therefore, the difference of Th1/Th2 balance between the B10.S and SJL/J mice is not due to the Ifng locus and does not account for the difference of susceptibility of these mice to persistent infection.
- Published
- 1999
- Full Text
- View/download PDF
26. Birth cohort distribution and screening for viraemic hepatitis C virus infections in Switzerland
- Author
-
Bruggmann, P, primary, Negro, F, additional, Bihl, F, additional, Blach, S, additional, Lavanchy, D, additional, Müllhaupt, B, additional, Razavi, H, additional, and Semela, D, additional
- Published
- 2015
- Full Text
- View/download PDF
27. Populational analysis reveals a link between complex viral escape from CD8+ T-Cell responses and protection in HCV infection
- Author
-
Kuntzen, T., Neumann-Haefelin, Christoph, Lennon, N., Talal, A. H., Carlson, J., Brumme, C., Timm, Jörg, Schmidt, J., Wunsch, K., Berical, A., Berlin, A. M., Adams, S., Young, S. K., Reyor, L. L., Kleyman, M., McMahon, C. M., Birch, C., Schulze zur Wiesch, J., Ledlie, T., Michael, K., Kodira, C., Roberts, A. D., Schneidewind, A., Lauer, G. M., Kim, A. Y., Rosen, H. R., Bihl, F., Cerny, A., Spengler, U., Brander, C., Galagan, J. E., Nusbaum, C., Walker, B. D., Lake-Bakaar, G. V., Daar, E. S., Jacobson, I. M., Gomperts, E. D., Edlin, B. R., Donfield, S. M., Chung, R. T., Marion, T., Birren, B. W., Marincola, F., Thimme, R., Carrington, M., Heckerman, D., Henn, M. R., and Allen, T. M.
- Subjects
Medizin - Published
- 2011
28. The new EASL guidelines for the management of chronic hepatitis B infection adapted for Swiss physicians
- Author
-
Bihl, F., Alaei, M., and Negro, F.
- Subjects
Antiviral Agents/therapeutic use ,Comorbidity ,Drug Resistance ,Female ,HIV Infections ,Health Personnel ,Hepatitis B virus/drug effects ,Hepatitis B virus/genetics ,Hepatitis B, Chronic/drug therapy ,Hepatitis B, Chronic/physiopathology ,Hepatitis B, Chronic/virology ,Humans ,Immunocompromised Host ,Liver Cirrhosis/prevention & control ,Male ,Practice Guidelines as Topic ,Practice Patterns, Physicians' ,Pregnancy ,Switzerland - Abstract
Since the arrival of several new antivirals and due to the growing molecular and clinical knowledge of hepatitis B virus (HBV) infection, therapy of hepatitis B has become complex. Clinical guidelines aim at streamlining medical attitudes: in this respect, the European Association for the Study of the Liver (EASL) recently issued clinical practice guidelines for the management of chronic hepatitis B. Guidelines made by international experts need however to be adapted to local health care systems. Here, we summarise the EASL guidelines with some minor modifications in order to be compatible with the particular Swiss situation, while discussing in more detail some aspects. Chronic hepatitis B is a complex disease with several phases where host and viral factors interact: the features of this continuous interplay need to be evaluated when choosing the most appropriate treatment. The EASL guidelines recommend, as first-line agents, using the most potent antivirals available with the optimal resistance profile, in order to abate HBV DNA as rapidly and as sustainably as possible. Once therapy has been started, the infection evolves and resistant viral strains may emerge. Rescue therapy needs to be started early with more potent agents lacking cross-resistance.
- Published
- 2010
29. Historical epidemiology of hepatitis C virus (HCV) in selected countries
- Author
-
Bruggmann, P, Berg, T, Øvrehus, ALH, Moreno, C, Brandão Mello, CE, Roudot-Thoraval, F, Marinho, RT, Sherman, M, Ryder, SD, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, AJ, Buti, M, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, MC, Müllhaupt, B, Myers, RP, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Rosenberg, WM, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, GE, Sievert, W, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, Hindman, SJ, Bruggmann, P, Berg, T, Øvrehus, ALH, Moreno, C, Brandão Mello, CE, Roudot-Thoraval, F, Marinho, RT, Sherman, M, Ryder, SD, Sperl, J, Akarca, U, Balık, I, Bihl, F, Bilodeau, M, Blasco, AJ, Buti, M, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hézode, C, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marotta, P, Mauss, S, Mendes Correa, MC, Müllhaupt, B, Myers, RP, Negro, F, Nemecek, V, Örmeci, N, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Rosenberg, WM, Sarmento-Castro, R, Sarrazin, C, Semela, D, Shiha, GE, Sievert, W, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Vogel, W, Waked, I, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Van Damme, P, Aleman, S, and Hindman, SJ
- Abstract
Chronic infection with hepatitis C virus (HCV) is a leading indicator for liver disease. New treatment options are becoming available, and there is a need to characterize the epidemiology and disease burden of HCV. Data for prevalence, viremia, genotype, diagnosis and treatment were obtained through literature searches and expert consensus for 16 countries. For some countries, data from centralized registries were used to estimate diagnosis and treatment rates. Data for the number of liver transplants and the proportion attributable to HCV were obtained from centralized databases. Viremic prevalence estimates varied widely between countries, ranging from 0.3% in Austria, England and Germany to 8.5% in Egypt. The largest viremic populations were in Egypt, with 6,358,000 cases in 2008 and Brazil with 2,106,000 cases in 2007. The age distribution of cases differed between countries. In most countries, prevalence rates were higher among males, reflecting higher rates of injection drug use. Diagnosis, treatment and transplant levels also differed considerably between countries. Reliable estimates characterizing HCV-infected populations are critical for addressing HCV-related morbidity and mortality. There is a need to quantify the burden of chronic HCV infection at the national level.
- Published
- 2014
30. Strategies to manage hepatitis C virus (HCV) disease burden
- Author
-
Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, Gower, E, Wedemeyer, H, Duberg, AS, Buti, M, Rosenberg, WM, Frankova, S, Esmat, G, Örmeci, N, Van Vlierberghe, H, Gschwantler, M, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Calinas, F, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cornberg, M, Cramp, ME, Dore, GJ, Doss, W, El-Sayed, MH, Ergör, G, Estes, C, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Guimarães Pessôa, M, Hézode, C, Hindman, SJ, Hofer, H, Husa, P, Idilman, R, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Lázaro, P, Marinho, RT, Marotta, P, Mauss, S, Mendes Correa, MC, Moreno, C, Müllhaupt, B, Myers, RP, Nemecek, V, Øvrehus, ALH, Parkes, J, Peltekian, KM, Ramji, A, Razavi, H, Reis, N, Roberts, SK, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Sarrazin, C, Semela, D, Sherman, M, Shiha, GE, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Vandijck, D, Vogel, W, Waked, I, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Negro, F, Sievert, W, and Gower, E
- Abstract
The number of hepatitis C virus (HCV) infections is projected to decline while those with advanced liver disease will increase. A modeling approach was used to forecast two treatment scenarios: (i) the impact of increased treatment efficacy while keeping the number of treated patients constant and (ii) increasing efficacy and treatment rate. This analysis suggests that successful diagnosis and treatment of a small proportion of patients can contribute significantly to the reduction of disease burden in the countries studied. The largest reduction in HCV-related morbidity and mortality occurs when increased treatment is combined with higher efficacy therapies, generally in combination with increased diagnosis. With a treatment rate of approximately 10%, this analysis suggests it is possible to achieve elimination of HCV (defined as a >90% decline in total infections by 2030). However, for most countries presented, this will require a 3-5 fold increase in diagnosis and/or treatment. Thus, building the public health and clinical provider capacity for improved diagnosis and treatment will be critical.
- Published
- 2014
31. The present and future disease burden of hepatitis C virus (HCV) infection with today's treatment paradigm
- Author
-
Razavi, H, Waked, I, Sarrazin, C, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, MC, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Buti, M, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, SJ, Hofer, H, Husa, P, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, A, Reis, N, Roberts, SK, Rosenberg, WM, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B, Estes, C, Razavi, H, Waked, I, Sarrazin, C, Myers, RP, Idilman, R, Calinas, F, Vogel, W, Mendes Correa, MC, Hézode, C, Lázaro, P, Akarca, U, Aleman, S, Balık, I, Berg, T, Bihl, F, Bilodeau, M, Blasco, AJ, Brandão Mello, CE, Bruggmann, P, Buti, M, Calleja, JL, Cheinquer, H, Christensen, PB, Clausen, M, Coelho, HSM, Cramp, ME, Dore, GJ, Doss, W, Duberg, AS, El-Sayed, MH, Ergör, G, Esmat, G, Falconer, K, Félix, J, Ferraz, MLG, Ferreira, PR, Frankova, S, García-Samaniego, J, Gerstoft, J, Giria, JA, Gonçales, FL, Gower, E, Gschwantler, M, Guimarães Pessôa, M, Hindman, SJ, Hofer, H, Husa, P, Kåberg, M, Kaita, KDE, Kautz, A, Kaymakoglu, S, Krajden, M, Krarup, H, Laleman, W, Lavanchy, D, Marinho, RT, Marotta, P, Mauss, S, Moreno, C, Murphy, K, Negro, F, Nemecek, V, Örmeci, N, Øvrehus, ALH, Parkes, J, Pasini, K, Peltekian, KM, Ramji, A, Reis, N, Roberts, SK, Rosenberg, WM, Roudot-Thoraval, F, Ryder, SD, Sarmento-Castro, R, Semela, D, Sherman, M, Shiha, GE, Sievert, W, Sperl, J, Stärkel, P, Stauber, RE, Thompson, AJ, Urbanek, P, Van Damme, P, van Thiel, I, Van Vlierberghe, H, Vandijck, D, Wedemeyer, H, Weis, N, Wiegand, J, Yosry, A, Zekry, A, Cornberg, M, Müllhaupt, B, and Estes, C
- Abstract
The disease burden of hepatitis C virus (HCV) is expected to increase as the infected population ages. A modelling approach was used to estimate the total number of viremic infections, diagnosed, treated and new infections in 2013. In addition, the model was used to estimate the change in the total number of HCV infections, the disease progression and mortality in 2013-2030. Finally, expert panel consensus was used to capture current treatment practices in each country. Using today's treatment paradigm, the total number of HCV infections is projected to decline or remain flat in all countries studied. However, in the same time period, the number of individuals with late-stage liver disease is projected to increase. This study concluded that the current treatment rate and efficacy are not sufficient to manage the disease burden of HCV. Thus, alternative strategies are required to keep the number of HCV individuals with advanced liver disease and liver-related deaths from increasing.
- Published
- 2014
32. TLR4 gene dosage contributes to endotoxin induced acute respiratory inflammation
- Author
-
Togbe, Dieudonnée, Schnyder-Candrian, S., Schnyder, B., Couillin, Isabelle, Maillet, I., Bihl, F., Malo, D., Ryffel, Bernhard, Quesniaux, Valérie, Immunologie et Embryologie Moléculaires (IEM), and Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.IMM]Life Sciences [q-bio]/Immunology - Published
- 2006
33. Toll-like receptor 2 is required for optimal control of Listeria monocytogenes infection
- Author
-
Torres, D., Barrier, M., Bihl, F., Quesniaux, Valérie, Maillet, I., Ryffel, Bernhard, Erard, François, Immunologie et Embryologie Moléculaires (IEM), and Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.IMM]Life Sciences [q-bio]/Immunology - Published
- 2004
34. Toll like receptor pathways in the immune responses to mycobacteria
- Author
-
Quesniaux, Valérie, Fremond, C., Jacobs, M., Parida, S., Nicolle, D., Yereemev, V., Bihl, F., Erard, François, Botha, T., Drennan, M., Mn, Soler, Bert M, Le, Schnyder, B., Ryffel, Bernhard, Immunologie et Embryologie Moléculaires (IEM), and Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.IMM]Life Sciences [q-bio]/Immunology - Published
- 2004
35. P1285 THE DISEASE BURDEN OF CHRONIC HEPATITIS C VIRUS (HCV) INFECTION IN SWITZERLAND
- Author
-
Bruggmann, P., primary, Negro, F., additional, Bihl, F., additional, Hindman, S., additional, Lavanchy, D., additional, Müllhaupt, B., additional, Razavi, H., additional, and Semela, D., additional
- Published
- 2014
- Full Text
- View/download PDF
36. P701 AUTOCHTHONOUS ACUTE HEPATITIS E IN SWITZERLAND: INCREASED RATE OF SEVERE MANIFESTATION IN MEN >50 YEARS
- Author
-
Doerig, C., primary, Moulin, H., additional, Müllhaupt, B., additional, Pache, I., additional, Bihl, F., additional, Telenti, A., additional, Sahli, R., additional, and Moradpour, D., additional
- Published
- 2014
- Full Text
- View/download PDF
37. Antigen-bearing dendritic cells from the sublingual mucosa recirculate to distant systemic lymphoid organs to prime mucosal CD8 T cells
- Author
-
Hervouet, C, primary, Luci, C, additional, Bekri, S, additional, Juhel, T, additional, Bihl, F, additional, Braud, V M, additional, Czerkinsky, C, additional, and Anjuère, F, additional
- Published
- 2014
- Full Text
- View/download PDF
38. Over-expression of Toll-like receptor 4 amplifies the host response to lipopolysaccharide and provides a survival advantage in transgenic mice
- Author
-
Beaubier, M., Alexandre Benedetto, Bihl, F., Lapointe, J. -M, Larivière, L., Laroche, L., Malo, D., Martel, D., Ryffel, B., Salez, L., Torres, D., Immunologie et Embryologie Moléculaires (IEM), and Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.IMM]Life Sciences [q-bio]/Immunology - Published
- 2003
39. Toll-Like Receptor 4 expression is required to control chronic Mycobacterium tuberculosis infection in mice
- Author
-
Abel, B., Thieblemont, N., Quesniaux, Valérie, Brown, N., Mpagi, J., Miyake, K., Bihl, F., Ryffel, Bernhard, Immunologie et Embryologie Moléculaires (IEM), and Université d'Orléans (UO)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
[SDV.IMM]Life Sciences [q-bio]/Immunology - Published
- 2002
40. Treatment of chronic hepatitis C genotype 1 with triple therapy comprising telaprevir or boceprevir.
- Author
-
Swiss Association for the Study of the Liver, Moradpour, D., Helbling, B., Cerny, A., De Gottardi, A., Heim, MH., Majno, P., Müllhaupt, B., Negro, F., Rubbia-Brandt, L., Semela, D., Vilei, SB., Bernsmeier, C., Bihl, F., Borovicka, J., Dill, M., Dufour, JF., Filipowicz, M., Geier, A., Gerlach, T., Giostra, E., Gonvers, JJ., Goossens, N., Gubler, C., Hadengue, A., Hellstern, M., Hirschi, C., Jochum, W., Krähenbühl, S., Kullak-Ublick, G., Lange, C., Lavanchy, D., Malinverni, R., McLin, V., Mentha, G., Mertens, JC., Nasser, S., Oneta, C., Pache, I., Sauter, B., Spahr, L., Steuerwald, M., Stickel, F., Stieger, B., Wehr, K., Zala, G., Swiss Association for the Study of the Liver, Moradpour, D., Helbling, B., Cerny, A., De Gottardi, A., Heim, MH., Majno, P., Müllhaupt, B., Negro, F., Rubbia-Brandt, L., Semela, D., Vilei, SB., Bernsmeier, C., Bihl, F., Borovicka, J., Dill, M., Dufour, JF., Filipowicz, M., Geier, A., Gerlach, T., Giostra, E., Gonvers, JJ., Goossens, N., Gubler, C., Hadengue, A., Hellstern, M., Hirschi, C., Jochum, W., Krähenbühl, S., Kullak-Ublick, G., Lange, C., Lavanchy, D., Malinverni, R., McLin, V., Mentha, G., Mertens, JC., Nasser, S., Oneta, C., Pache, I., Sauter, B., Spahr, L., Steuerwald, M., Stickel, F., Stieger, B., Wehr, K., and Zala, G.
- Abstract
Hepatitis C virus (HCV) infection is a leading cause of chronic hepatitis, liver cirrhosis and hepatocellular carcinoma worldwide. Two first-generation protease inhibitors, telaprevir and boceprevir, have recently been approved for the treatment of chronic hepatitis C genotype 1. Triple therapy comprising pegylated interferon-α, ribavirin and telaprevir or boceprevir increases sustained virological response rates to ~70% and allows to shorten treatment duration in ~½ of treatment-naïve patients with chronic hepatitis C genotype 1. Sustained virological response rates in treatment-experienced patients depend on the response to previous treatment, ranging from >80% in previous relapsers to ~30% in previous null responders. These advances come at the expense of new adverse effects and increased cost. In addition, treatment of chronic hepatitis C will become more complex. In these times of changing medical practice, the present expert opinion statement by the Swiss Association for the Study of the Liver shall provide guidance on the treatment of chronic hepatitis C with triple therapy comprising telaprevir or boceprevir.
- Published
- 2012
41. Hyperimmune anti-HBs plasma as alternative to commercial immunoglobulins for prevention of HBV recurrence after liver transplantation
- Author
-
Bihl, F, Russmann, S, Gurtner, V, Di Giammarino, L, Pizzi-Bosman, L, Michel, M, Cerny, A, Hadengue, A, Majno, P, Giostra, E, Castelli, D, Mentha, G, Bihl, F, Russmann, S, Gurtner, V, Di Giammarino, L, Pizzi-Bosman, L, Michel, M, Cerny, A, Hadengue, A, Majno, P, Giostra, E, Castelli, D, and Mentha, G
- Abstract
BACKGROUND: Hepatitis B immune globulins (HBIG) in combination with nucleos(t)ide analogues (NA) are effectively used for the prevention of hepatitis B virus (HBV) recurrence after liver transplantation (LT). However, associated treatment costs for HBIG are exceedingly high. METHODS: Fresh frozen plasma obtained from blood donors with high anti-HBs levels (hyperimmune plasma, HIP) containing at least 4,500 IU anti-HBs was used as alternative treatment for HBV recurrence prophylaxis post-LT. RESULTS: Twenty-one HBV-related LT recipients received HIP starting at transplantation, followed by long-term combination treatment with NA. Mean follow-up time was 4.5 years (range 0.5-12.6) and each patient received on average 8.2 HIP per year (range 5.8-11.4). Anti-HBs terminal elimination kinetic after HIP administration was 20.6 days (range 13.8-30.9), which is comparable to values reported for commercial HBIG products. All 21 patients remained free of HBV recurrence during follow-up and no transfusion-transmitted infection or other serious complication was observed. Seven patients developed reversible mild transfusion reactions. The cost for one HIP unit was USD 140; average yearly HBIG treatment cost was USD 1,148 per patient, as compared to USD 25,000-100,000 for treatment with commercial HBIG. CONCLUSION: The results of this study suggest that the use of HIP may be a useful and economical approach for the prevention of HBV recurrence post-LT if used in combination with NA. Additional prospective controlled studies in larger populations are needed to confirm these results.
- Published
- 2010
42. Cellular immune responses and disease control in acute AIDS-associated Kaposi's sarcoma
- Author
-
Bihl, F, Berger, C, Chisholm, J V, Henry, L M, Bertisch, B, Trojan, A, Nadal, D, Speck, R F, Flepp, M, Brander, C, Mueller, N J, Bihl, F, Berger, C, Chisholm, J V, Henry, L M, Bertisch, B, Trojan, A, Nadal, D, Speck, R F, Flepp, M, Brander, C, and Mueller, N J
- Abstract
Kaposi's sarcoma-associated herpesvirus (KSHV) specific T cell responses and KSHV viremia were analyzed in seven HIV-infected patients with active Kaposi's sarcoma lesions who initiated highly active antiretroviral therapy, and were compared between patients with improved Kaposi's sarcoma and those with progressive Kaposi's sarcoma requiring further systemic chemotherapy. Patients with controlled Kaposi's sarcoma disease demonstrated undetectable Kaposi's sarcoma viremia together with KSHV-specific CD8 T cells secreting interferon-gamma and tumor necrosis factor-alpha, whereas progressors showed increasing viremia with weak or no T-cell responses. These data point toward a potential role of KSHV-specific immunity in the control of AIDS-associated Kaposi's sarcoma.
- Published
- 2009
43. Extensive HLA class I allele promiscuity among viral CTL epitopes
- Author
-
Frahm, N., Yusim, K., Suscovich, T., Adams, S., Sidney, J., Hraber, P., Hewitt, H., Linde, C., Kavanagh, D., Woodberry, Tonia, Henry, L., Faircloth, K., Listgarten, J., Kadie, C., Jojic, N., Sango, K., Brown, N., Pae, E., Zaman, M., Bihl, F., Khatri, A., John, M., Mallal, S., Marincola, F., Walker, B., Sette, A., Heckerman, D., Korber, B., Brander, C., Frahm, N., Yusim, K., Suscovich, T., Adams, S., Sidney, J., Hraber, P., Hewitt, H., Linde, C., Kavanagh, D., Woodberry, Tonia, Henry, L., Faircloth, K., Listgarten, J., Kadie, C., Jojic, N., Sango, K., Brown, N., Pae, E., Zaman, M., Bihl, F., Khatri, A., John, M., Mallal, S., Marincola, F., Walker, B., Sette, A., Heckerman, D., Korber, B., and Brander, C.
- Abstract
Promiscuous binding of T helper epitopes to MHC class II molecules has been well established, but few examples of promiscuous class I-restricted epitopes exist. To address the extent of promiscuity of HLA class I peptides, responses to 242 well-defined viral epitopes were tested in 100 subjects regardless of the individuals HLA type. Surprisingly, half of all detected responses were seen in the absence of the originally reported restricting HLA class I allele, and only 3% of epitopes were recognized exclusively in the presence of their original allele. Functional assays confirmed the frequent recognition of HLA class I-restricted T cell epitopes on several alternative alleles across HLA class I supertypes and encoded on different class I loci. These data have significant implications for the understanding of MHC class I-restricted antigen presentation and vaccine development.
- Published
- 2007
44. A genetic approach to study the pathogenesis of Theiler's virus persistent infection
- Author
-
Azoulay-Cayla, A., Brahic, M., Bureau, J. F., Bihl, F., Dethlefs, S., Fiette, L., Jarousse, N., Larsson-Sciard, E. L., Cécile Martinat, Mcallister, A., Michiels, T., Pena Rossi, C., Virus Lents, Institut Pasteur [Paris]-Centre National de la Recherche Scientifique (CNRS), and Institut Pasteur [Paris] (IP)-Centre National de la Recherche Scientifique (CNRS)
- Subjects
Mice, Knockout ,Chimera ,[SDV]Life Sciences [q-bio] ,H-2 Antigens ,Mice, Inbred Strains ,Myelin Basic Protein ,Mice ,Capsid ,Phenotype ,Theilovirus ,DNA, Viral ,Animals ,ComputingMilieux_MISCELLANEOUS ,Poliomyelitis - Abstract
International audience
- Published
- 1997
45. Impact of HLA-B alleles, epitope binding affinity, functional avidity, and viral coinfection on the immunodominance of virus-specific CTL responses
- Author
-
Bihl, F., Frahm, N., Di Giammarino, L., Sidney, J., John, M., Yusim, K., Woodberry, T., Sango, K., Hewitt, H.S., Henry, L., Linde, C.H., Chisholm, J.V., Zaman, T.M., Pae, E., Mallal, S., Walker, B.D., Sette, A., Korber, B.T., Heckerman, D., Brander, C., Bihl, F., Frahm, N., Di Giammarino, L., Sidney, J., John, M., Yusim, K., Woodberry, T., Sango, K., Hewitt, H.S., Henry, L., Linde, C.H., Chisholm, J.V., Zaman, T.M., Pae, E., Mallal, S., Walker, B.D., Sette, A., Korber, B.T., Heckerman, D., and Brander, C.
- Abstract
Immunodominance is variably used to describe either the most frequently detectable response among tested individuals or the strongest response within a single individual, yet factors determining either inter- or intraindividual immunodominance are still poorly understood. More than 90 individuals were tested against 184 HIV- and 92 EBV-derived, previously defined CTL epitopes. The data show that HLA-B-restricted epitopes were significantly more frequently recognized than HLA-A- or HLA-C-restricted epitopes. HLA-B-restricted epitopes also induced responses of higher magnitude than did either HLA-A- or HLA-C-restricted epitopes, although this comparison only reached statistical significance for EBV epitopes. For both viruses, the magnitude and frequency of recognition were correlated with each other, but not with the epitope binding affinity to the restricting HLA allele. The presence or absence of HIV coinfection did not impact EBV epitope immunodominance patterns significantly. Peptide titration studies showed that the magnitude of responses was associated with high functional avidity, requiring low concentration of cognate peptide to respond in in vitro assays. The data support the important role of HLA-B alleles in antiviral immunity and afford a better understanding of the factors contributing to inter- and intraindividual immunodominance.
- Published
- 2006
46. 301 PEGYLATED INTERFERON-ALPHA POTENTLY AUGMENTS NK CELL ANTIVIRAL EFFECTOR FUNCTION
- Author
-
Micco, L., primary, Peppa, D., additional, Loggi, E., additional, Schurich, A., additional, Carmela, C., additional, Panno, A. Martello, additional, Bihl, F., additional, Bernardi, M., additional, Andreone, P., additional, and Maini, M.K., additional
- Published
- 2011
- Full Text
- View/download PDF
47. 3 POPULATIONAL ANALYSIS REVEALS A LINK BETWEEN COMPLEX VIRAL ESCAPE FROM CD8+ T-CELL RESPONSES AND PROTECTION IN HCV INFECTION
- Author
-
Kuntzen, T., primary, Neumann-Haefelin, C., additional, Lennon, N., additional, Talal, A.H., additional, Carlson, J., additional, Brumme, C., additional, Timm, J., additional, Schmidt, J., additional, Wunsch, K., additional, Berical, A., additional, Berlin, A.M., additional, Adams, S., additional, Young, S.K., additional, Reyor, L.L., additional, Kleyman, M., additional, McMahon, C.M., additional, Birch, C., additional, Schulze zur Wiesch, J., additional, Ledlie, T., additional, Michael, K., additional, Kodira, C., additional, Roberts, A.D., additional, Schneidewind, A., additional, Lauer, G.M., additional, Kim, A.Y., additional, Rosen, H.R., additional, Bihl, F., additional, Cerny, A., additional, Spengler, U., additional, Brander, C., additional, Galagan, J.E., additional, Nusbaum, C., additional, Walker, B.D., additional, Lake-Bakaar, G.V., additional, Daar, E.S., additional, Jacobson, I.M., additional, Gomperts, E.D., additional, Edlin, B.R., additional, Donfield, S.M., additional, Chung, R.T., additional, Marion, T., additional, Birren, B.W., additional, Marincola, F., additional, Thimme, R., additional, Carrington, M., additional, Heckerman, D., additional, Henn, M.R., additional, and Allen, T.M., additional
- Published
- 2011
- Full Text
- View/download PDF
48. OC-12 Pegylated interferon-alpha potently augments NK cell antiviral effector function in chronic hepatitis B
- Author
-
Micco, L., primary, Peppa, D., additional, Loggi, E., additional, Schurich, A., additional, Cursaro, C., additional, Panno, A. Martello, additional, Bihl, F., additional, Bernardi, M., additional, Andreone, P., additional, and Maini, M.K., additional
- Published
- 2011
- Full Text
- View/download PDF
49. 9 DIFFERENTIAL EFFECTS OF PEGYLATED INTERFERON ALPHA THERAPY ON INNATE AND ADAPTIVE IMMUNE RESPONSES IN CHRONIC HEPATITIS B
- Author
-
Micco, L., primary, Peppa, D., additional, Loggi, E., additional, Martello Panno, A., additional, Shurich, A., additional, Cursaro, C., additional, Bihl, F., additional, Bernardi, M., additional, Andreone, P., additional, and Maini, M.K., additional
- Published
- 2010
- Full Text
- View/download PDF
50. 619 NEGATIVE CORRELATION BETWEEN HBSAG SERUM LEVELS AND HBV-SPECIFIC IMMUNE RESPONSES
- Author
-
Loggi, E., primary, Bihl, F., additional, Micco, L., additional, Cursaro, C., additional, Gramenzi, A., additional, Cannoletta, F., additional, Granieri, C., additional, Bernardi, M., additional, and Andreone, P., additional
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.